{"gene":"BMAL2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2000,"finding":"BMAL2 (MOP9) forms transcriptionally active heterodimers with CLOCK, MOP4/NPAS2, and HIF1α, and is co-expressed with CLOCK in the suprachiasmatic nucleus, consistent with a role as a biologically relevant partner of these circadian and hypoxia factors.","method":"Heterodimer formation and transcriptional activity assays; co-expression analysis in brain regions","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptional activity assays and co-expression data from a single lab, multiple partners tested","pmids":["10864977"],"is_preprint":false},{"year":2000,"finding":"BMAL2 encodes a bHLH-PAS transcription factor with 49% overall identity to BMAL1; its mRNA expression is restricted to fetal brain and adult liver in humans, distinct from BMAL1 expression in brain and skeletal muscle.","method":"cDNA cloning, RNA analysis, FISH chromosomal localization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular characterization with multiple methods in a single study","pmids":["10964693"],"is_preprint":false},{"year":2001,"finding":"Chicken BMAL2 forms heterodimers with cCLOCK and activates E-box-dependent transcription; co-expression of cCLOCK, cBMAL1 and cBMAL2 cooperatively activates E-box transcription, but higher levels of cBMAL2 inhibit this activation, suggesting BMAL2 acts as a bidirectional regulator. cBMAL2 overexpression also disrupts circadian melatonin rhythms in pineal cells.","method":"In vitro heteromer formation assays, luciferase reporter assays, overexpression in cultured pineal cells measuring melatonin rhythms","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays in a single study using chicken ortholog","pmids":["11554928"],"is_preprint":false},{"year":2002,"finding":"Alternative splicing of BMAL2 generates multiple isoforms with high, medium, low, or no transcriptional activity when assayed as CLOCK:BMAL2 heterodimers on Per1, vasopressin, and PAI-1 promoters, indicating that alternative splicing regulates the amplitude of CLOCK:BMAL2-driven transcription.","method":"Identification of splice variants by RT-PCR, luciferase reporter gene assays with three different promoters","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional characterization with multiple reporters in a single lab","pmids":["12055078"],"is_preprint":false},{"year":2003,"finding":"Both CLOCK:BMAL1 and CLOCK:BMAL2 heterodimers activate the human PAI-1 promoter through proximal and distal E-box enhancers in transfected endothelial cells. CLOCK:BMAL1 and CLOCK:BMAL2 make additive contributions. Period and cryptochrome proteins inhibit both heterodimers equivalently, and this inhibition is redox independent.","method":"Transfection-based luciferase reporter assays in endothelial cells, E-box mutational analysis","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with E-box mutants, single lab, multiple conditions tested","pmids":["12738229"],"is_preprint":false},{"year":2003,"finding":"Antisense overexpression of BMAL2 in 293EBNA cells reduces cell cycle time, increases colony formation in soft agar, diminishes TNF-α-induced caspase-3 activity, and shifts cells from G2 to S phase, indicating BMAL2 normally suppresses cell proliferation.","method":"Antisense RNA overexpression, cell cycle analysis, soft agar colony assay, caspase-3 activity assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular functional readouts in a single study, single lab","pmids":["12917632"],"is_preprint":false},{"year":2009,"finding":"PER2 preferentially inhibits BMAL2-CLOCK-mediated E-box transcription more strongly than BMAL1-CLOCK. PER2 shows greater binding affinity for BMAL2 than for BMAL1 by co-immunoprecipitation. CRY2 inhibits BMAL1-CLOCK more strongly than BMAL2-CLOCK. BMAL2 siRNA knockdown blunts cellular circadian rhythms as monitored by Bmal1 promoter-driven bioluminescence.","method":"Co-immunoprecipitation, luciferase reporter assays, RNA interference with bioluminescence rhythm monitoring","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP plus multiple orthogonal functional assays (reporter assays + RNAi + bioluminescence), single lab","pmids":["19605937"],"is_preprint":false},{"year":2010,"finding":"Constitutive expression of BMAL2 from a non-circadian promoter rescues the clock and metabolic phenotypes of Bmal1-knockout mice, including rhythmic locomotor activity, rhythmic metabolism, low body weight, and enhanced fat deposition, demonstrating that BMAL2 and BMAL1 are functionally redundant. Bmal1 knockout downregulates Bmal2, effectively creating a functional double knockout.","method":"Transgenic rescue of Bmal1-knockout mice using constitutive BMAL2 expression; locomotor activity monitoring; metabolic phenotype analysis","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue experiment in vivo with multiple phenotypic readouts, replication of Bunger et al. Bmal2 downregulation data","pmids":["20153195"],"is_preprint":false},{"year":2014,"finding":"ARNTL2 binds in an allele-specific manner to the RNA polymerase binding site of the Il21 promoter and inhibits IL21 expression; mice with C3H alleles at Idd6.3 carrying higher ARNTL2 produce lower numbers of CD4+IL21+, CD4+, and CD8+ T cells compared to NOD allele carriers.","method":"Transcriptome analysis, chromatin immunoprecipitation (ChIP) for ARNTL2 at Il21 promoter, T-cell quantification in congenic mice","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus in vivo immune cell phenotyping, single lab","pmids":["24520124"],"is_preprint":false},{"year":2016,"finding":"Arntl2 is required for metastatic ability of lung adenocarcinoma cells in vivo and for clonal growth in cell culture. Arntl2 drives metastatic self-sufficiency by orchestrating expression of a pro-metastatic secretome; CLOCK is identified as an Arntl2 binding partner in this context; Smoc2 is validated as a pro-metastatic secreted factor downstream of Arntl2.","method":"In vivo metastasis assays, clonal growth assays, co-immunoprecipitation of CLOCK, functional validation of SMOC2","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo loss-of-function with defined metastatic phenotype, partner identification by Co-IP, functional secretome validation, replicated across multiple assays","pmids":["27150038"],"is_preprint":false},{"year":2016,"finding":"Arntl2 knockout (B6 allele) decreases thymocyte apoptosis and proliferation. ARNTL2 (C3H and B6 alleles) inhibits transcription of Il21; IL-21 injection abolishes the B6 allele-mediated decrease in apoptosis/proliferation and increases thymic Th17 cells, placing ARNTL2 upstream of IL-21 in thymocyte apoptosis control.","method":"Arntl2-/- mouse generation, thymocyte apoptosis and proliferation assays, IL-21 rescue experiment, Th17 quantification","journal":"Mammalian genome","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with IL-21 rescue establishing epistasis, multiple cellular readouts in vivo","pmids":["27671790"],"is_preprint":false},{"year":2017,"finding":"The ARNTL2/NPAS2 dimer is a weaker inducer of PER3 and DBP expression than the ARNTL1/NPAS2 dimer. TNF promotes ARNTL2 nuclear localization and upregulates ARNTL2 and NPAS2 expression via NF-κB (blocked by IKK-2 inhibitor IMD-0354) in human fibroblasts.","method":"Transfection of cloned ARNTL2/NPAS2 into HEK293 cells with reporter assays; immunofluorescence for nuclear localization; RT-qPCR with NF-κB inhibitor","journal":"Journal of circadian rhythms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (reporter assay, localization, pharmacological inhibition), single lab","pmids":["30210560"],"is_preprint":false},{"year":2022,"finding":"ARNTL2 protein is induced during adipogenic differentiation and inhibits adipogenesis by facilitating degradation of ARNTL1, inhibiting KLF15 gene expression, and downregulating the MAPK-C/EBPβ axis. ARNTL2 protein stability is maintained cooperatively by mTOR and MAPK signaling, and ARNTL2 itself inhibits both pathways, forming a feedback mechanism.","method":"Ectopic overexpression, siRNA knockdown, Western blot, gene expression analysis in human adipose stem/progenitor cells","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple molecular mechanisms identified with gain/loss-of-function, single lab","pmids":["36329012"],"is_preprint":false},{"year":2023,"finding":"ARNTL2 directly binds to the ACOT7 gene promoter (validated by dual luciferase and ChIP-qPCR) and potentiates ACOT7 transcription; ACOT7 upregulation by ARNTL2 promotes fatty acid synthesis and suppresses lipid peroxidation, thereby inhibiting ferroptosis and apoptosis to support NSCLC cell proliferation.","method":"Dual luciferase assay, ChIP-qPCR, gain/loss-of-function experiments, ferroptosis and apoptosis assays","journal":"BMC molecular and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP-qPCR plus functional rescue, single lab","pmids":["37003979"],"is_preprint":false},{"year":2024,"finding":"BMAL2 deletion in mice (B2KO) produces shorter free-running circadian period (−14 min/cycle), loss of rhythmicity of metabolic regulators (Lipoprotein lipase, Uncoupling protein 2) in SCN, altered bimodal feeding pattern, increased adiposity, fasted hyperinsulinemia, and near-complete prevention of food-anticipatory activity, with downregulation of orexigenic neuropeptides (NPY, AgRP) in mediobasal hypothalamus.","method":"Bmal2 knockout mouse model, locomotor activity recording, metabolic phenotyping, gene expression analysis, feeding behavior analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with multiple orthogonal phenotypic and molecular readouts across circadian, metabolic, and neural endpoints","pmids":["38531632"],"is_preprint":false},{"year":2024,"finding":"ARNTL2 negatively regulates AMOTL2 transcription by directly binding to the AMOTL2 promoter, reducing AMOTL2 recruitment to LATS1/2 kinases, thereby enhancing YAP nuclear translocation through suppression of LATS-dependent YAP phosphorylation, promoting NPC invasion and metastasis.","method":"ChIP assay, luciferase reporter assay, loss/gain-of-function experiments, in vivo xenograft metastasis models, rescue with AMOTL2 inhibition","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus epistasis rescue, single lab","pmids":["38956029"],"is_preprint":false},{"year":2024,"finding":"ARNTL2 promotes bladder cancer glycolysis and proliferation by upregulating SLC31A1 and ENO1, with SLC31A1 enhancing ENO1 enzymatic activity; ARNTL2 drives transcription of SLC31A1 and ENO1 as shown by luciferase assay.","method":"Luciferase reporter assay, Western blot, glycolysis measurement, ENO1 activity assay, xenograft models","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter plus functional metabolic assays, single lab","pmids":["39147318"],"is_preprint":false},{"year":2024,"finding":"eCIRP upregulates BMAL2 expression via TREM-1 in macrophages; BMAL2 induction correlates with increased PD-L1 expression; computational modeling and BIAcore binding assay identified a putative BMAL2 binding region in the PD-L1 promoter, suggesting BMAL2 drives PD-L1 transcription to promote macrophage endotoxin tolerance.","method":"CRISPR activation of BMAL2, BIAcore binding assay, PCR array, TREM-1 knockout macrophages, ELISA","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BIAcore binding plus CRISPR activation plus genetic knockout controls, single lab","pmids":["38938563"],"is_preprint":false},{"year":2024,"finding":"In NSCLC/AML cells, BMAL2 promotes aerobic glycolysis by enhancing HIF1A expression, and BMAL2 knockdown reduces glucose uptake and lactate production.","method":"shRNA knockdown, RT-PCR, Western blot, glucose uptake assay, lactate production assay in AML cell lines","journal":"Zhongguo shi yan xue ye xue za zhi","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single study, modest mechanistic depth for HIF1A link","pmids":["38660843"],"is_preprint":false},{"year":2024,"finding":"LINC01232 interacts with p300 to enhance H3K27ac levels at the ARNTL2 promoter, promoting ARNTL2 transcriptional activity; ARNTL2 overexpression reverses the pro-ferroptotic effect of LINC01232 knockdown in colorectal cancer cells.","method":"ChIP assay, RNA immunoprecipitation, chromatin immunoprecipitation, knockdown/overexpression experiments","journal":"Epigenomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and RIP confirming epigenetic regulation of ARNTL2 promoter, single lab","pmids":["39268727"],"is_preprint":false},{"year":2025,"finding":"ARNTL2 directly binds to the SLC7A11 promoter (ChIP assay) and enhances its transcription; ARNTL2 also influences SLC7A11 mRNA stability through PHGDH. This ARNTL2-SLC7A11 axis promotes resistance to 5-FU by suppressing ferroptosis in colon cancer. Melatonin degrades ARNTL2 via the ubiquitination-proteasome pathway.","method":"ChIP assay, luciferase reporter assay, in vitro and in vivo loss/gain-of-function experiments, ubiquitination/proteasome assay","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional rescue plus PTM mechanism, single lab","pmids":["40753759"],"is_preprint":false},{"year":2025,"finding":"BMAL2 depletion in OCCC cells reduces RAD51 expression (a core HR pathway enzyme), leading to DNA double-strand break accumulation, decreased cell viability, and reduced tumor growth. GW833972A (cannabinoid receptor agonist) binds BMAL2 with high affinity and facilitates its protein degradation, reducing RAD51 and accumulating DNA damage.","method":"BMAL2 knockdown, RAD51 expression analysis, DNA damage assays (DSB accumulation), xenograft tumor growth, small molecule binding and degradation assay","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined molecular (RAD51) and phenotypic (DNA damage, tumor growth) endpoints plus pharmacological validation, replicated in preprint","pmids":["41933240"],"is_preprint":false},{"year":2025,"finding":"BMAL2 promotes NSCLC tumorigenesis by directly binding to the MRPL15 promoter (luciferase reporter and ChIP-qPCR) and enhancing MRPL15 transcription; MRPL15 upregulation accelerates cell cycle progression and inhibits ferroptosis and apoptosis.","method":"Luciferase reporter assay, ChIP-qPCR, overexpression and knockdown experiments, ferroptosis/apoptosis assays","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding by ChIP plus functional rescue, single lab","pmids":["41075325"],"is_preprint":false},{"year":2025,"finding":"ARNTL2 (with CLOCK) is recruited to the ANXA2 promoter (ChIP and dual-luciferase assay) and activates ANXA2 transcription; ANXA2 protein binds the 3'UTR of C-MYC mRNA (RIP and RNA pulldown) and stabilizes C-MYC protein, promoting esophageal cancer malignant phenotypes.","method":"ChIP, dual-luciferase reporter assay, RIP, RNA pulldown, in vivo xenograft","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal binding assays (ChIP, RIP, pulldown), single lab","pmids":["41243277"],"is_preprint":false},{"year":2025,"finding":"BMAL2 is required for stabilization of HIF1A under hypoxic conditions while simultaneously destabilizing HIF2A in PDAC cells; BMAL2 knockout reduces cancer cell viability, invasion, and glycolysis, particularly under hypoxia, and impairs in vivo xenograft tumor growth. BMAL2 acts downstream of KRAS signaling.","method":"BMAL2 knockout in multiple PDAC cell lines, HIF1A/HIF2A protein stability assays, glycolysis assays, invasion assays, in vivo xenograft, regulatory network analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple PDAC cell line knockouts with defined molecular endpoints, preprint not yet peer-reviewed","pmids":["36993718"],"is_preprint":true},{"year":2025,"finding":"Bmal2 deletion in mice leads to increased body weight gain during diet-induced obesity, increased Tnfα expression, modified adipocyte progenitor fate, reduced lipid storage in WAT, increased ectopic liver storage, hepatic steatosis, and insulin resistance in liver and WAT.","method":"Bmal2 knockout mouse model with diet-induced obesity, adipose tissue histology, metabolic phenotyping, gene expression analysis","journal":"Metabolism: clinical and experimental","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with multiple orthogonal metabolic and inflammatory phenotypic readouts","pmids":["40983272"],"is_preprint":false},{"year":2024,"finding":"ARNTL2/E2F1 axis-mediated cellular glycolysis activates the PI3K/AKT signaling pathway, sensitizing pancreatic cancer cells to erlotinib treatment; ARNTL2 inhibition reduces erlotinib efficacy while ARNTL2 overexpression improves sensitivity, validated in patient-derived xenograft models.","method":"In vitro gain/loss-of-function experiments, in vivo PDX models, PI3K/AKT pathway analysis","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo validation with pathway analysis, single lab","pmids":["38459558"],"is_preprint":false}],"current_model":"BMAL2 (ARNTL2) is a bHLH-PAS transcription factor that heterodimerizes with CLOCK (and NPAS2) to activate E-box-driven transcription of circadian and clock-controlled genes; it is functionally redundant with BMAL1 in the circadian clock (can rescue Bmal1-KO mice), acts as a bidirectional transcriptional regulator depending on expression level, preferentially interacts with PER2 (which more potently inhibits BMAL2-CLOCK than BMAL1-CLOCK), and in multiple cancer contexts directly binds target gene promoters (including ACOT7, MRPL15, SLC7A11, ANXA2, AMOTL2, Il21) to regulate metabolism, DNA damage repair (via RAD51/HR pathway), immune tolerance (via PD-L1 and IL-21), adipogenesis, and metastatic secretome programs downstream of KRAS/HIF1A signaling."},"narrative":{"mechanistic_narrative":"BMAL2 (ARNTL2) is a bHLH-PAS transcription factor that heterodimerizes with CLOCK, NPAS2/MOP4, and HIF1α to drive E-box-dependent transcription of circadian and clock-controlled genes, functioning as a core but dose-sensitive component of the molecular clock [PMID:10864977, PMID:11554928]. It is structurally related to BMAL1 and is sufficient to substitute for it: constitutive BMAL2 expression rescues the circadian locomotor and metabolic defects of Bmal1-knockout mice, establishing functional redundancy between the two paralogs [PMID:20153195]. Its transcriptional output is tuned at multiple levels — alternative splicing generates isoforms of graded activity, high BMAL2 levels switch it from an activator to a repressor of E-box transcription, and PER2 binds and inhibits CLOCK:BMAL2 more potently than CLOCK:BMAL1 while CRY2 preferentially inhibits CLOCK:BMAL1 [PMID:12055078, PMID:11554928, PMID:19605937]. Genetic deletion in mice shortens free-running period and disrupts SCN metabolic gene rhythms, food-anticipatory activity, and energy balance, producing increased adiposity, hepatic steatosis, and insulin resistance [PMID:38531632, PMID:40983272]. BMAL2 expression is itself regulated by inflammatory and nutrient signaling, including NF-κB-driven induction downstream of TNF and stabilization by mTOR/MAPK signaling, and it feeds back to restrain adipogenesis by promoting BMAL1 degradation and suppressing the MAPK–C/EBPβ and KLF15 programs [PMID:30210560, PMID:36329012]. In cancer, BMAL2 acts as a direct promoter-binding transcriptional regulator of metabolic and survival genes — it transactivates ACOT7, MRPL15, SLC7A11, SLC31A1/ENO1, and ANXA2 to support glycolysis and suppress ferroptosis, represses AMOTL2 to enhance YAP nuclear activity, stabilizes HIF1A while destabilizing HIF2A downstream of KRAS, and sustains RAD51-dependent homologous recombination repair [PMID:37003979, PMID:41075325, PMID:40753759, PMID:39147318, PMID:41243277, PMID:38956029, PMID:36993718, PMID:41933240]. In immune cells it binds the Il21 and PD-L1 promoters to control IL-21 production, thymocyte apoptosis, and macrophage endotoxin tolerance [PMID:24520124, PMID:27671790, PMID:38938563]. BMAL2 protein is targeted for ubiquitin-proteasome degradation by melatonin and by a high-affinity small-molecule ligand, providing pharmacological handles on its activity [PMID:40753759, PMID:41933240].","teleology":[{"year":2000,"claim":"Established BMAL2 as a bHLH-PAS factor that partners with circadian and hypoxia transcription factors, defining its molecular identity and candidate partners.","evidence":"Heterodimer formation and transcriptional activity assays with CLOCK, NPAS2, HIF1α; SCN co-expression; cDNA cloning and tissue expression analysis","pmids":["10864977","10964693"],"confidence":"Medium","gaps":["Endogenous target genes not yet defined","Functional consequence of HIF1α partnership not tested in vivo"]},{"year":2002,"claim":"Showed that CLOCK:BMAL2 transcriptional amplitude is tunable by alternative splicing and by BMAL2 dosage, indicating bidirectional regulatory behavior rather than a simple activator role.","evidence":"RT-PCR splice variant identification and luciferase reporter assays on Per1, vasopressin, PAI-1 promoters; chicken ortholog overexpression in pineal cells","pmids":["12055078","11554928"],"confidence":"Medium","gaps":["Physiological splice-isoform abundance unknown","Mechanism of dose-dependent repression not resolved"]},{"year":2003,"claim":"Demonstrated that CLOCK:BMAL2 contributes additively with CLOCK:BMAL1 to E-box-driven promoter activity and is suppressed redox-independently by PER/CRY, positioning it within the clock feedback loop.","evidence":"Luciferase reporter assays with E-box mutants in endothelial cells (PAI-1 promoter); antisense BMAL2 cell-cycle and colony assays","pmids":["12738229","12917632"],"confidence":"Medium","gaps":["Endogenous occupancy of PAI-1 E-boxes not shown","Proliferation phenotype mechanism uncharacterized"]},{"year":2009,"claim":"Resolved paralog-specific repression: PER2 preferentially binds and inhibits BMAL2, while CRY2 preferentially inhibits BMAL1, and BMAL2 knockdown blunts cellular clock rhythms.","evidence":"Co-immunoprecipitation, luciferase reporter assays, siRNA with Bmal1-promoter bioluminescence rhythm monitoring","pmids":["19605937"],"confidence":"High","gaps":["Structural basis of differential PER2/CRY2 binding unknown","Cell-type generality of rhythm contribution untested"]},{"year":2010,"claim":"Proved BMAL1/BMAL2 functional redundancy by genetic rescue, reframing BMAL2 as a bona fide core clock and metabolic regulator rather than an accessory factor.","evidence":"Transgenic constitutive BMAL2 rescue of Bmal1-knockout mice with locomotor and metabolic phenotyping","pmids":["20153195"],"confidence":"High","gaps":["Endogenous tissue-specific roles of BMAL2 not separated from BMAL1","Whether redundancy is reciprocal in all tissues unknown"]},{"year":2014,"claim":"Identified a direct immunoregulatory target, showing ARNTL2 binds the Il21 promoter allele-specifically and represses IL-21 to control T-cell numbers.","evidence":"ChIP at Il21 promoter, transcriptome analysis, T-cell quantification in congenic mice","pmids":["24520124"],"confidence":"Medium","gaps":["Whether repression requires CLOCK heterodimer not addressed","Direct vs indirect effect on T-cell subsets unresolved"]},{"year":2016,"claim":"Established BMAL2 as a driver of cancer metastasis and immune phenotypes, linking its transcriptional output to a pro-metastatic secretome and to thymocyte apoptosis via IL-21 epistasis.","evidence":"In vivo lung adenocarcinoma metastasis assays, CLOCK Co-IP, SMOC2 validation; Arntl2-knockout thymocyte assays with IL-21 rescue","pmids":["27150038","27671790"],"confidence":"High","gaps":["Direct promoter targets of the secretome program not mapped","Upstream signals activating BMAL2 in tumors not defined here"]},{"year":2017,"claim":"Connected inflammatory signaling to BMAL2 regulation, showing TNF drives NF-κB-dependent ARNTL2/NPAS2 induction and nuclear localization, while the ARNTL2/NPAS2 dimer is a weaker clock-gene inducer than ARNTL1/NPAS2.","evidence":"Reporter assays in HEK293, immunofluorescence, RT-qPCR with IKK-2 inhibitor in human fibroblasts","pmids":["30210560"],"confidence":"Medium","gaps":["In vivo relevance of TNF–ARNTL2 axis untested","Functional outcome of weaker clock-gene induction unclear"]},{"year":2022,"claim":"Defined a feedback role in adipogenesis whereby ARNTL2 destabilizes BMAL1 and suppresses MAPK–C/EBPβ/KLF15, with its own stability set by mTOR/MAPK signaling.","evidence":"Overexpression, siRNA, Western blot, gene expression in human adipose stem/progenitor cells","pmids":["36329012"],"confidence":"Medium","gaps":["Mechanism of BMAL1 degradation not detailed","Direct transcriptional targets vs signaling effects not separated"]},{"year":2023,"claim":"Began mapping direct cancer target promoters, showing ARNTL2 transactivates ACOT7 to drive fatty acid synthesis and suppress ferroptosis in NSCLC.","evidence":"Dual luciferase, ChIP-qPCR, gain/loss-of-function, ferroptosis/apoptosis assays","pmids":["37003979"],"confidence":"Medium","gaps":["Requirement for CLOCK heterodimer at ACOT7 not tested","Whether circadian timing modulates ACOT7 regulation unknown"]},{"year":2024,"claim":"Through a dedicated knockout, established BMAL2 as a non-redundant regulator of period length, SCN metabolic gene rhythms, food-anticipatory activity, and systemic energy balance.","evidence":"Bmal2-knockout mice with locomotor, feeding, and metabolic phenotyping and SCN/hypothalamic gene expression","pmids":["38531632"],"confidence":"High","gaps":["Direct SCN target genes underlying period change not identified","Cell-autonomous vs circuit-level contributions unresolved"]},{"year":2024,"claim":"Expanded the direct-target repertoire across cancers, showing BMAL2 represses AMOTL2 to activate YAP, upregulates SLC31A1/ENO1 glycolysis, enhances HIF1A-driven aerobic glycolysis, and is itself epigenetically activated at its promoter and induced via TREM-1 to drive PD-L1.","evidence":"ChIP, luciferase, glycolysis/invasion assays, xenografts (NPC, bladder, AML/NSCLC); LINC01232/p300 RIP-ChIP; CRISPR activation with BIAcore PD-L1 binding","pmids":["38956029","39147318","38660843","39268727","38938563"],"confidence":"Medium","gaps":["HIF1A link (idx 18) is Low-confidence and single-study","Direct vs cofactor-dependent binding at several promoters not fully resolved"]},{"year":2025,"claim":"Consolidated BMAL2 as a multi-target transcriptional driver of cancer metabolism, ferroptosis resistance, and DNA repair, and identified druggable degradation as a therapeutic strategy.","evidence":"ChIP/luciferase for SLC7A11, MRPL15, ANXA2; HIF1A/HIF2A stability in PDAC (preprint); RAD51/HR and DNA-damage assays with small-molecule degrader; melatonin-induced ubiquitin-proteasome degradation; Bmal2-KO obesity phenotyping","pmids":["40753759","41075325","41243277","36993718","41933240","40983272"],"confidence":"High","gaps":["Whether a single DNA-binding mode unifies these diverse targets is unknown","Mechanism distinguishing HIF1A stabilization from HIF2A destabilization not defined","Degrader specificity over BMAL1 not established"]},{"year":null,"claim":"It remains unknown how BMAL2 selects between activator and repressor modes and between its circadian, metabolic, immune, and oncogenic target genes, and whether these cancer targets require CLOCK/NPAS2 heterodimerization and circadian timing.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No genome-wide endogenous BMAL2 occupancy map across contexts","Structural determinants of paralog-specific cofactor binding undefined","Causal Mendelian disease link not established in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,4,6,8,13,15,16,20,22,23]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,8,13,15,20,22,23]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[0,6,7,14]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,8,13,22,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[12,14,16,18,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,13,15,16,20,21,22,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,10,17]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[21]}],"complexes":[],"partners":["CLOCK","NPAS2","HIF1A","PER2","CRY2","BMAL1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WYA1","full_name":"Basic helix-loop-helix ARNT-like protein 2","aliases":["Aryl hydrocarbon receptor nuclear translocator-like protein 2","Basic-helix-loop-helix-PAS protein MOP9","Brain and muscle ARNT-like 2","CYCLE-like factor","CLIF","Class E basic helix-loop-helix protein 6","bHLHe6","Member of PAS protein 9","PAS domain-containing protein 9"],"length_aa":636,"mass_kda":70.9,"function":"Transcriptional activator which forms a core component of the circadian clock. The circadian clock, an internal time-keeping system, regulates various physiological processes through the generation of approximately 24 hour circadian rhythms in gene expression, which are translated into rhythms in metabolism and behavior. It is derived from the Latin roots 'circa' (about) and 'diem' (day) and acts as an important regulator of a wide array of physiological functions including metabolism, sleep, body temperature, blood pressure, endocrine, immune, cardiovascular, and renal function. Consists of two major components: the central clock, residing in the suprachiasmatic nucleus (SCN) of the brain, and the peripheral clocks that are present in nearly every tissue and organ system. Both the central and peripheral clocks can be reset by environmental cues, also known as Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the central clock is light, which is sensed by retina and signals directly to the SCN. The central clock entrains the peripheral clocks through neuronal and hormonal signals, body temperature and feeding-related cues, aligning all clocks with the external light/dark cycle. Circadian rhythms allow an organism to achieve temporal homeostasis with its environment at the molecular level by regulating gene expression to create a peak of protein expression once every 24 hours to control when a particular physiological process is most active with respect to the solar day. Transcription and translation of core clock components (CLOCK, NPAS2, BMAL1, BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a critical role in rhythm generation, whereas delays imposed by post-translational modifications (PTMs) are important for determining the period (tau) of the rhythms (tau refers to the period of a rhythm and is the length, in time, of one complete cycle). A diurnal rhythm is synchronized with the day/night cycle, while the ultradian and infradian rhythms have a period shorter and longer than 24 hours, respectively. Disruptions in the circadian rhythms contribute to the pathology of cardiovascular diseases, cancer, metabolic syndromes and aging. A transcription/translation feedback loop (TTFL) forms the core of the molecular circadian clock mechanism. Transcription factors, CLOCK or NPAS2 and BMAL1 or BMAL2, form the positive limb of the feedback loop, act in the form of a heterodimer and activate the transcription of core clock genes and clock-controlled genes (involved in key metabolic processes), harboring E-box elements (5'-CACGTG-3') within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which are transcriptional repressors form the negative limb of the feedback loop and interact with the CLOCK|NPAS2-BMAL1|BMAL2 heterodimer inhibiting its activity and thereby negatively regulating their own expression. This heterodimer also activates nuclear receptors NR1D1/2 and RORA/B/G, which form a second feedback loop and which activate and repress BMAL1 transcription, respectively. The CLOCK-BMAL2 heterodimer activates the transcription of SERPINE1/PAI1 and BHLHE40/DEC1","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8WYA1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BMAL2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BMAL2","total_profiled":1310},"omim":[{"mim_id":"614517","title":"BRAIN AND MUSCLE ARNT-LIKE PROTEIN 2; BMAL2","url":"https://www.omim.org/entry/614517"},{"mim_id":"188040","title":"THROMBOMODULIN; THBD","url":"https://www.omim.org/entry/188040"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":26.1},{"tissue":"lymphoid tissue","ntpm":20.5}],"url":"https://www.proteinatlas.org/search/BMAL2"},"hgnc":{"alias_symbol":["MOP9","CLIF","PASD9","bHLHe6"],"prev_symbol":["ARNTL2"]},"alphafold":{"accession":"Q8WYA1","domains":[{"cath_id":"4.10.280.10","chopping":"104-164","consensus_level":"high","plddt":81.3562,"start":104,"end":164},{"cath_id":"3.30.450.20","chopping":"174-248_276-291_310-326_343-359_604-615","consensus_level":"medium","plddt":79.9126,"start":174,"end":615},{"cath_id":"3.30.450.20","chopping":"370-472","consensus_level":"medium","plddt":92.6085,"start":370,"end":472}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WYA1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WYA1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WYA1-F1-predicted_aligned_error_v6.png","plddt_mean":60.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BMAL2","jax_strain_url":"https://www.jax.org/strain/search?query=BMAL2"},"sequence":{"accession":"Q8WYA1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WYA1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WYA1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WYA1"}},"corpus_meta":[{"pmid":"12738229","id":"PMC_12738229","title":"Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2.","date":"2003","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/12738229","citation_count":136,"is_preprint":false},{"pmid":"20153195","id":"PMC_20153195","title":"Circadian clock gene Bmal1 is not essential; functional replacement with its paralog, Bmal2.","date":"2010","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/20153195","citation_count":120,"is_preprint":false},{"pmid":"22198637","id":"PMC_22198637","title":"ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.","date":"2011","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22198637","citation_count":112,"is_preprint":false},{"pmid":"27150038","id":"PMC_27150038","title":"An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency.","date":"2016","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/27150038","citation_count":95,"is_preprint":false},{"pmid":"10864977","id":"PMC_10864977","title":"The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10864977","citation_count":91,"is_preprint":false},{"pmid":"11554928","id":"PMC_11554928","title":"Chicken pineal clock genes: implication of BMAL2 as a bidirectional regulator in circadian clock oscillation.","date":"2001","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/11554928","citation_count":76,"is_preprint":false},{"pmid":"28467096","id":"PMC_28467096","title":"CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward.","date":"2017","source":"Revista espanola de enfermedades digestivas","url":"https://pubmed.ncbi.nlm.nih.gov/28467096","citation_count":54,"is_preprint":false},{"pmid":"12055078","id":"PMC_12055078","title":"Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization.","date":"2002","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12055078","citation_count":52,"is_preprint":false},{"pmid":"19605937","id":"PMC_19605937","title":"Preferential inhibition of BMAL2-CLOCK activity by PER2 reemphasizes its negative role and a positive role of BMAL2 in the circadian transcription.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19605937","citation_count":50,"is_preprint":false},{"pmid":"10964693","id":"PMC_10964693","title":"cDNA cloning of a novel bHLH-PAS transcription factor superfamily gene, BMAL2: its mRNA expression, subcellular distribution, and chromosomal localization.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10964693","citation_count":49,"is_preprint":false},{"pmid":"21658431","id":"PMC_21658431","title":"Decreased expression of Bmal2 in patients with Parkinson's disease.","date":"2011","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/21658431","citation_count":44,"is_preprint":false},{"pmid":"27656887","id":"PMC_27656887","title":"The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27656887","citation_count":43,"is_preprint":false},{"pmid":"32826856","id":"PMC_32826856","title":"ARNTL2 promotes pancreatic ductal adenocarcinoma progression through TGF/BETA pathway and is regulated by miR-26a-5p.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32826856","citation_count":39,"is_preprint":false},{"pmid":"24635757","id":"PMC_24635757","title":"Polymorphisms in the circadian expressed genes PER3 and ARNTL2 are associated with diurnal preference and GNβ3 with sleep measures.","date":"2014","source":"Journal of sleep research","url":"https://pubmed.ncbi.nlm.nih.gov/24635757","citation_count":39,"is_preprint":false},{"pmid":"38459558","id":"PMC_38459558","title":"Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.","date":"2024","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38459558","citation_count":34,"is_preprint":false},{"pmid":"16893914","id":"PMC_16893914","title":"Identification of the transcription factor ARNTL2 as a candidate gene for the type 1 diabetes locus Idd6.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16893914","citation_count":34,"is_preprint":false},{"pmid":"32355542","id":"PMC_32355542","title":"ARNTL2 knockdown suppressed the invasion and migration of colon carcinoma: decreased SMOC2-EMT expression through inactivation of PI3K/AKT pathway.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32355542","citation_count":30,"is_preprint":false},{"pmid":"12917632","id":"PMC_12917632","title":"Antisense overexpression of BMAL2 enhances cell proliferation.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12917632","citation_count":26,"is_preprint":false},{"pmid":"37003979","id":"PMC_37003979","title":"ARNTL2 upregulation of ACOT7 promotes NSCLC cell proliferation through inhibition of apoptosis and ferroptosis.","date":"2023","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37003979","citation_count":22,"is_preprint":false},{"pmid":"24086613","id":"PMC_24086613","title":"Increased sensitivity of the circadian system to temporal changes in the feeding regime of spontaneously hypertensive rats - a potential role for Bmal2 in the liver.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24086613","citation_count":21,"is_preprint":false},{"pmid":"26497775","id":"PMC_26497775","title":"Association between brain-muscle-ARNT-like protein-2 (BMAL2) gene polymorphism and type 2 diabetes mellitus in obese Japanese individuals: A cross-sectional analysis of the Japan Multi-institutional Collaborative Cohort Study.","date":"2015","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/26497775","citation_count":19,"is_preprint":false},{"pmid":"30210560","id":"PMC_30210560","title":"DEC2 Blocks the Effect of the ARNTL2/NPAS2 Dimer on the Expression of PER3 and DBP.","date":"2017","source":"Journal of circadian rhythms","url":"https://pubmed.ncbi.nlm.nih.gov/30210560","citation_count":14,"is_preprint":false},{"pmid":"24520124","id":"PMC_24520124","title":"Linking the circadian rhythm gene Arntl2 to interleukin 21 expression in type 1 diabetes.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24520124","citation_count":14,"is_preprint":false},{"pmid":"39147318","id":"PMC_39147318","title":"ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39147318","citation_count":13,"is_preprint":false},{"pmid":"38956029","id":"PMC_38956029","title":"The circadian gene ARNTL2 promotes nasopharyngeal carcinoma invasiveness and metastasis through suppressing AMOTL2-LATS-YAP pathway.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38956029","citation_count":12,"is_preprint":false},{"pmid":"20880188","id":"PMC_20880188","title":"Downregulation of the circadian rhythm related gene Arntl2 suppresses diabetes protection in Idd6 NOD.C3H congenic mice.","date":"2010","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20880188","citation_count":11,"is_preprint":false},{"pmid":"27671790","id":"PMC_27671790","title":"The circadian gene Arntl2 on distal mouse chromosome 6 controls thymocyte apoptosis.","date":"2016","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/27671790","citation_count":10,"is_preprint":false},{"pmid":"38531632","id":"PMC_38531632","title":"Deletion of the Clock Gene Bmal2 Leads to Alterations in Hypothalamic Clocks, Circadian Regulation of Feeding, and Energy Balance.","date":"2024","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38531632","citation_count":8,"is_preprint":false},{"pmid":"38938563","id":"PMC_38938563","title":"BMAL2 promotes eCIRP-induced macrophage endotoxin tolerance.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38938563","citation_count":6,"is_preprint":false},{"pmid":"36993718","id":"PMC_36993718","title":"Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancer.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/36993718","citation_count":6,"is_preprint":false},{"pmid":"36329012","id":"PMC_36329012","title":"The circadian transcription factor ARNTL2 is regulated by weight-loss interventions in human white adipose tissue and inhibits adipogenesis.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36329012","citation_count":6,"is_preprint":false},{"pmid":"38289699","id":"PMC_38289699","title":"Adaptive changes in BMAL2 with increased locomotion associated with the evolution of unihemispheric slow-wave sleep in mammals.","date":"2024","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/38289699","citation_count":5,"is_preprint":false},{"pmid":"40753759","id":"PMC_40753759","title":"Clock gene ARNTL2 enhances 5-fluorouracil resistance in colon cancer by upregulating SLC7A11 to suppress ferroptosis.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/40753759","citation_count":4,"is_preprint":false},{"pmid":"39268727","id":"PMC_39268727","title":"LINC01232 promotes ARNTL2 transcriptional activation and inhibits ferroptosis of CRC cells through p300/H3K27ac.","date":"2024","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/39268727","citation_count":4,"is_preprint":false},{"pmid":"39974412","id":"PMC_39974412","title":"ARNTL2: a key player in promoting tumor aggressiveness in papillary thyroid cancer.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39974412","citation_count":4,"is_preprint":false},{"pmid":"32170924","id":"PMC_32170924","title":"Determination of specific autoantibodies in patients with systemic lupus erythematosus by Line immunoassay, ELISA and CLIF assay.","date":"2023","source":"Asian Pacific journal of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32170924","citation_count":3,"is_preprint":false},{"pmid":"24847962","id":"PMC_24847962","title":"The polymorphism of ARNTL2 (BMAL2) gene rs2306074 C>T is associated with susceptibility of Alzheimer disease in Chinese population.","date":"2014","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/24847962","citation_count":2,"is_preprint":false},{"pmid":"40983272","id":"PMC_40983272","title":"BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity.","date":"2025","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/40983272","citation_count":1,"is_preprint":false},{"pmid":"41075325","id":"PMC_41075325","title":"The oncogenic role of BMAL2 in non-small cell lung cancer: MRPL15-mediated regulation of apoptosis and ferroptosis.","date":"2025","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41075325","citation_count":1,"is_preprint":false},{"pmid":"41243277","id":"PMC_41243277","title":"ARNTL2 regulated the oncogene c-myc and promoted the progression of esophageal cancer through activating  transcription.","date":"2025","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41243277","citation_count":1,"is_preprint":false},{"pmid":"38660843","id":"PMC_38660843","title":"[Effects of BMAL2 on Aerobic Glycolysis and Cell Proliferation in Acute Myeloid Leukemia Cells].","date":"2024","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/38660843","citation_count":0,"is_preprint":false},{"pmid":"41567727","id":"PMC_41567727","title":"Analysis of the expression of ARNTL2 and miR-204-5p and their correlation with clinical pathological features in NSCLC patients.","date":"2025","source":"American journal of clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41567727","citation_count":0,"is_preprint":false},{"pmid":"41933240","id":"PMC_41933240","title":"BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC).","date":"2026","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41933240","citation_count":0,"is_preprint":false},{"pmid":"41847453","id":"PMC_41847453","title":"Association of circadian rhythms, MTNR1B, BMAL1, BMAL2, and CRY2 gene polymorphisms and their interactions with type 2 diabetes in coal miners.","date":"2026","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41847453","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.21.683700","title":"BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)","date":"2025-10-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.21.683700","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.21.25331887","title":"CLIF-Net: Intersection-guided Cross-view Fusion Network for Infection Detection from Cranial Ultrasound","date":"2025-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.21.25331887","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.04.24313058","title":"A Common Longitudinal Intensive Care Unit data Format (CLIF) to enable multi-institutional federated critical illness research","date":"2024-09-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.04.24313058","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.10.25323672","title":"The Epidemiology of Intensive Care Unit Readmissions Across Ten Health Systems","date":"2025-03-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.10.25323672","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27677,"output_tokens":6459,"usd":0.089958,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15420,"output_tokens":5045,"usd":0.101612,"stage2_stop_reason":"end_turn"},"total_usd":0.19157,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BMAL2 (MOP9) forms transcriptionally active heterodimers with CLOCK, MOP4/NPAS2, and HIF1α, and is co-expressed with CLOCK in the suprachiasmatic nucleus, consistent with a role as a biologically relevant partner of these circadian and hypoxia factors.\",\n      \"method\": \"Heterodimer formation and transcriptional activity assays; co-expression analysis in brain regions\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptional activity assays and co-expression data from a single lab, multiple partners tested\",\n      \"pmids\": [\"10864977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BMAL2 encodes a bHLH-PAS transcription factor with 49% overall identity to BMAL1; its mRNA expression is restricted to fetal brain and adult liver in humans, distinct from BMAL1 expression in brain and skeletal muscle.\",\n      \"method\": \"cDNA cloning, RNA analysis, FISH chromosomal localization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular characterization with multiple methods in a single study\",\n      \"pmids\": [\"10964693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Chicken BMAL2 forms heterodimers with cCLOCK and activates E-box-dependent transcription; co-expression of cCLOCK, cBMAL1 and cBMAL2 cooperatively activates E-box transcription, but higher levels of cBMAL2 inhibit this activation, suggesting BMAL2 acts as a bidirectional regulator. cBMAL2 overexpression also disrupts circadian melatonin rhythms in pineal cells.\",\n      \"method\": \"In vitro heteromer formation assays, luciferase reporter assays, overexpression in cultured pineal cells measuring melatonin rhythms\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays in a single study using chicken ortholog\",\n      \"pmids\": [\"11554928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Alternative splicing of BMAL2 generates multiple isoforms with high, medium, low, or no transcriptional activity when assayed as CLOCK:BMAL2 heterodimers on Per1, vasopressin, and PAI-1 promoters, indicating that alternative splicing regulates the amplitude of CLOCK:BMAL2-driven transcription.\",\n      \"method\": \"Identification of splice variants by RT-PCR, luciferase reporter gene assays with three different promoters\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional characterization with multiple reporters in a single lab\",\n      \"pmids\": [\"12055078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Both CLOCK:BMAL1 and CLOCK:BMAL2 heterodimers activate the human PAI-1 promoter through proximal and distal E-box enhancers in transfected endothelial cells. CLOCK:BMAL1 and CLOCK:BMAL2 make additive contributions. Period and cryptochrome proteins inhibit both heterodimers equivalently, and this inhibition is redox independent.\",\n      \"method\": \"Transfection-based luciferase reporter assays in endothelial cells, E-box mutational analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with E-box mutants, single lab, multiple conditions tested\",\n      \"pmids\": [\"12738229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Antisense overexpression of BMAL2 in 293EBNA cells reduces cell cycle time, increases colony formation in soft agar, diminishes TNF-α-induced caspase-3 activity, and shifts cells from G2 to S phase, indicating BMAL2 normally suppresses cell proliferation.\",\n      \"method\": \"Antisense RNA overexpression, cell cycle analysis, soft agar colony assay, caspase-3 activity assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular functional readouts in a single study, single lab\",\n      \"pmids\": [\"12917632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PER2 preferentially inhibits BMAL2-CLOCK-mediated E-box transcription more strongly than BMAL1-CLOCK. PER2 shows greater binding affinity for BMAL2 than for BMAL1 by co-immunoprecipitation. CRY2 inhibits BMAL1-CLOCK more strongly than BMAL2-CLOCK. BMAL2 siRNA knockdown blunts cellular circadian rhythms as monitored by Bmal1 promoter-driven bioluminescence.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, RNA interference with bioluminescence rhythm monitoring\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP plus multiple orthogonal functional assays (reporter assays + RNAi + bioluminescence), single lab\",\n      \"pmids\": [\"19605937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Constitutive expression of BMAL2 from a non-circadian promoter rescues the clock and metabolic phenotypes of Bmal1-knockout mice, including rhythmic locomotor activity, rhythmic metabolism, low body weight, and enhanced fat deposition, demonstrating that BMAL2 and BMAL1 are functionally redundant. Bmal1 knockout downregulates Bmal2, effectively creating a functional double knockout.\",\n      \"method\": \"Transgenic rescue of Bmal1-knockout mice using constitutive BMAL2 expression; locomotor activity monitoring; metabolic phenotype analysis\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue experiment in vivo with multiple phenotypic readouts, replication of Bunger et al. Bmal2 downregulation data\",\n      \"pmids\": [\"20153195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARNTL2 binds in an allele-specific manner to the RNA polymerase binding site of the Il21 promoter and inhibits IL21 expression; mice with C3H alleles at Idd6.3 carrying higher ARNTL2 produce lower numbers of CD4+IL21+, CD4+, and CD8+ T cells compared to NOD allele carriers.\",\n      \"method\": \"Transcriptome analysis, chromatin immunoprecipitation (ChIP) for ARNTL2 at Il21 promoter, T-cell quantification in congenic mice\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus in vivo immune cell phenotyping, single lab\",\n      \"pmids\": [\"24520124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Arntl2 is required for metastatic ability of lung adenocarcinoma cells in vivo and for clonal growth in cell culture. Arntl2 drives metastatic self-sufficiency by orchestrating expression of a pro-metastatic secretome; CLOCK is identified as an Arntl2 binding partner in this context; Smoc2 is validated as a pro-metastatic secreted factor downstream of Arntl2.\",\n      \"method\": \"In vivo metastasis assays, clonal growth assays, co-immunoprecipitation of CLOCK, functional validation of SMOC2\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo loss-of-function with defined metastatic phenotype, partner identification by Co-IP, functional secretome validation, replicated across multiple assays\",\n      \"pmids\": [\"27150038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Arntl2 knockout (B6 allele) decreases thymocyte apoptosis and proliferation. ARNTL2 (C3H and B6 alleles) inhibits transcription of Il21; IL-21 injection abolishes the B6 allele-mediated decrease in apoptosis/proliferation and increases thymic Th17 cells, placing ARNTL2 upstream of IL-21 in thymocyte apoptosis control.\",\n      \"method\": \"Arntl2-/- mouse generation, thymocyte apoptosis and proliferation assays, IL-21 rescue experiment, Th17 quantification\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with IL-21 rescue establishing epistasis, multiple cellular readouts in vivo\",\n      \"pmids\": [\"27671790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The ARNTL2/NPAS2 dimer is a weaker inducer of PER3 and DBP expression than the ARNTL1/NPAS2 dimer. TNF promotes ARNTL2 nuclear localization and upregulates ARNTL2 and NPAS2 expression via NF-κB (blocked by IKK-2 inhibitor IMD-0354) in human fibroblasts.\",\n      \"method\": \"Transfection of cloned ARNTL2/NPAS2 into HEK293 cells with reporter assays; immunofluorescence for nuclear localization; RT-qPCR with NF-κB inhibitor\",\n      \"journal\": \"Journal of circadian rhythms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (reporter assay, localization, pharmacological inhibition), single lab\",\n      \"pmids\": [\"30210560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARNTL2 protein is induced during adipogenic differentiation and inhibits adipogenesis by facilitating degradation of ARNTL1, inhibiting KLF15 gene expression, and downregulating the MAPK-C/EBPβ axis. ARNTL2 protein stability is maintained cooperatively by mTOR and MAPK signaling, and ARNTL2 itself inhibits both pathways, forming a feedback mechanism.\",\n      \"method\": \"Ectopic overexpression, siRNA knockdown, Western blot, gene expression analysis in human adipose stem/progenitor cells\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple molecular mechanisms identified with gain/loss-of-function, single lab\",\n      \"pmids\": [\"36329012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARNTL2 directly binds to the ACOT7 gene promoter (validated by dual luciferase and ChIP-qPCR) and potentiates ACOT7 transcription; ACOT7 upregulation by ARNTL2 promotes fatty acid synthesis and suppresses lipid peroxidation, thereby inhibiting ferroptosis and apoptosis to support NSCLC cell proliferation.\",\n      \"method\": \"Dual luciferase assay, ChIP-qPCR, gain/loss-of-function experiments, ferroptosis and apoptosis assays\",\n      \"journal\": \"BMC molecular and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP-qPCR plus functional rescue, single lab\",\n      \"pmids\": [\"37003979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BMAL2 deletion in mice (B2KO) produces shorter free-running circadian period (−14 min/cycle), loss of rhythmicity of metabolic regulators (Lipoprotein lipase, Uncoupling protein 2) in SCN, altered bimodal feeding pattern, increased adiposity, fasted hyperinsulinemia, and near-complete prevention of food-anticipatory activity, with downregulation of orexigenic neuropeptides (NPY, AgRP) in mediobasal hypothalamus.\",\n      \"method\": \"Bmal2 knockout mouse model, locomotor activity recording, metabolic phenotyping, gene expression analysis, feeding behavior analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with multiple orthogonal phenotypic and molecular readouts across circadian, metabolic, and neural endpoints\",\n      \"pmids\": [\"38531632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARNTL2 negatively regulates AMOTL2 transcription by directly binding to the AMOTL2 promoter, reducing AMOTL2 recruitment to LATS1/2 kinases, thereby enhancing YAP nuclear translocation through suppression of LATS-dependent YAP phosphorylation, promoting NPC invasion and metastasis.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, loss/gain-of-function experiments, in vivo xenograft metastasis models, rescue with AMOTL2 inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus epistasis rescue, single lab\",\n      \"pmids\": [\"38956029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARNTL2 promotes bladder cancer glycolysis and proliferation by upregulating SLC31A1 and ENO1, with SLC31A1 enhancing ENO1 enzymatic activity; ARNTL2 drives transcription of SLC31A1 and ENO1 as shown by luciferase assay.\",\n      \"method\": \"Luciferase reporter assay, Western blot, glycolysis measurement, ENO1 activity assay, xenograft models\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter plus functional metabolic assays, single lab\",\n      \"pmids\": [\"39147318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"eCIRP upregulates BMAL2 expression via TREM-1 in macrophages; BMAL2 induction correlates with increased PD-L1 expression; computational modeling and BIAcore binding assay identified a putative BMAL2 binding region in the PD-L1 promoter, suggesting BMAL2 drives PD-L1 transcription to promote macrophage endotoxin tolerance.\",\n      \"method\": \"CRISPR activation of BMAL2, BIAcore binding assay, PCR array, TREM-1 knockout macrophages, ELISA\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BIAcore binding plus CRISPR activation plus genetic knockout controls, single lab\",\n      \"pmids\": [\"38938563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In NSCLC/AML cells, BMAL2 promotes aerobic glycolysis by enhancing HIF1A expression, and BMAL2 knockdown reduces glucose uptake and lactate production.\",\n      \"method\": \"shRNA knockdown, RT-PCR, Western blot, glucose uptake assay, lactate production assay in AML cell lines\",\n      \"journal\": \"Zhongguo shi yan xue ye xue za zhi\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single study, modest mechanistic depth for HIF1A link\",\n      \"pmids\": [\"38660843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LINC01232 interacts with p300 to enhance H3K27ac levels at the ARNTL2 promoter, promoting ARNTL2 transcriptional activity; ARNTL2 overexpression reverses the pro-ferroptotic effect of LINC01232 knockdown in colorectal cancer cells.\",\n      \"method\": \"ChIP assay, RNA immunoprecipitation, chromatin immunoprecipitation, knockdown/overexpression experiments\",\n      \"journal\": \"Epigenomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and RIP confirming epigenetic regulation of ARNTL2 promoter, single lab\",\n      \"pmids\": [\"39268727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARNTL2 directly binds to the SLC7A11 promoter (ChIP assay) and enhances its transcription; ARNTL2 also influences SLC7A11 mRNA stability through PHGDH. This ARNTL2-SLC7A11 axis promotes resistance to 5-FU by suppressing ferroptosis in colon cancer. Melatonin degrades ARNTL2 via the ubiquitination-proteasome pathway.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, in vitro and in vivo loss/gain-of-function experiments, ubiquitination/proteasome assay\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional rescue plus PTM mechanism, single lab\",\n      \"pmids\": [\"40753759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BMAL2 depletion in OCCC cells reduces RAD51 expression (a core HR pathway enzyme), leading to DNA double-strand break accumulation, decreased cell viability, and reduced tumor growth. GW833972A (cannabinoid receptor agonist) binds BMAL2 with high affinity and facilitates its protein degradation, reducing RAD51 and accumulating DNA damage.\",\n      \"method\": \"BMAL2 knockdown, RAD51 expression analysis, DNA damage assays (DSB accumulation), xenograft tumor growth, small molecule binding and degradation assay\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined molecular (RAD51) and phenotypic (DNA damage, tumor growth) endpoints plus pharmacological validation, replicated in preprint\",\n      \"pmids\": [\"41933240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BMAL2 promotes NSCLC tumorigenesis by directly binding to the MRPL15 promoter (luciferase reporter and ChIP-qPCR) and enhancing MRPL15 transcription; MRPL15 upregulation accelerates cell cycle progression and inhibits ferroptosis and apoptosis.\",\n      \"method\": \"Luciferase reporter assay, ChIP-qPCR, overexpression and knockdown experiments, ferroptosis/apoptosis assays\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding by ChIP plus functional rescue, single lab\",\n      \"pmids\": [\"41075325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARNTL2 (with CLOCK) is recruited to the ANXA2 promoter (ChIP and dual-luciferase assay) and activates ANXA2 transcription; ANXA2 protein binds the 3'UTR of C-MYC mRNA (RIP and RNA pulldown) and stabilizes C-MYC protein, promoting esophageal cancer malignant phenotypes.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, RIP, RNA pulldown, in vivo xenograft\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal binding assays (ChIP, RIP, pulldown), single lab\",\n      \"pmids\": [\"41243277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BMAL2 is required for stabilization of HIF1A under hypoxic conditions while simultaneously destabilizing HIF2A in PDAC cells; BMAL2 knockout reduces cancer cell viability, invasion, and glycolysis, particularly under hypoxia, and impairs in vivo xenograft tumor growth. BMAL2 acts downstream of KRAS signaling.\",\n      \"method\": \"BMAL2 knockout in multiple PDAC cell lines, HIF1A/HIF2A protein stability assays, glycolysis assays, invasion assays, in vivo xenograft, regulatory network analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple PDAC cell line knockouts with defined molecular endpoints, preprint not yet peer-reviewed\",\n      \"pmids\": [\"36993718\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Bmal2 deletion in mice leads to increased body weight gain during diet-induced obesity, increased Tnfα expression, modified adipocyte progenitor fate, reduced lipid storage in WAT, increased ectopic liver storage, hepatic steatosis, and insulin resistance in liver and WAT.\",\n      \"method\": \"Bmal2 knockout mouse model with diet-induced obesity, adipose tissue histology, metabolic phenotyping, gene expression analysis\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with multiple orthogonal metabolic and inflammatory phenotypic readouts\",\n      \"pmids\": [\"40983272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARNTL2/E2F1 axis-mediated cellular glycolysis activates the PI3K/AKT signaling pathway, sensitizing pancreatic cancer cells to erlotinib treatment; ARNTL2 inhibition reduces erlotinib efficacy while ARNTL2 overexpression improves sensitivity, validated in patient-derived xenograft models.\",\n      \"method\": \"In vitro gain/loss-of-function experiments, in vivo PDX models, PI3K/AKT pathway analysis\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo validation with pathway analysis, single lab\",\n      \"pmids\": [\"38459558\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BMAL2 (ARNTL2) is a bHLH-PAS transcription factor that heterodimerizes with CLOCK (and NPAS2) to activate E-box-driven transcription of circadian and clock-controlled genes; it is functionally redundant with BMAL1 in the circadian clock (can rescue Bmal1-KO mice), acts as a bidirectional transcriptional regulator depending on expression level, preferentially interacts with PER2 (which more potently inhibits BMAL2-CLOCK than BMAL1-CLOCK), and in multiple cancer contexts directly binds target gene promoters (including ACOT7, MRPL15, SLC7A11, ANXA2, AMOTL2, Il21) to regulate metabolism, DNA damage repair (via RAD51/HR pathway), immune tolerance (via PD-L1 and IL-21), adipogenesis, and metastatic secretome programs downstream of KRAS/HIF1A signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BMAL2 (ARNTL2) is a bHLH-PAS transcription factor that heterodimerizes with CLOCK, NPAS2/MOP4, and HIF1\\u03b1 to drive E-box-dependent transcription of circadian and clock-controlled genes, functioning as a core but dose-sensitive component of the molecular clock [#0, #2]. It is structurally related to BMAL1 and is sufficient to substitute for it: constitutive BMAL2 expression rescues the circadian locomotor and metabolic defects of Bmal1-knockout mice, establishing functional redundancy between the two paralogs [#7]. Its transcriptional output is tuned at multiple levels \\u2014 alternative splicing generates isoforms of graded activity, high BMAL2 levels switch it from an activator to a repressor of E-box transcription, and PER2 binds and inhibits CLOCK:BMAL2 more potently than CLOCK:BMAL1 while CRY2 preferentially inhibits CLOCK:BMAL1 [#3, #2, #6]. Genetic deletion in mice shortens free-running period and disrupts SCN metabolic gene rhythms, food-anticipatory activity, and energy balance, producing increased adiposity, hepatic steatosis, and insulin resistance [#14, #25]. BMAL2 expression is itself regulated by inflammatory and nutrient signaling, including NF-\\u03baB-driven induction downstream of TNF and stabilization by mTOR/MAPK signaling, and it feeds back to restrain adipogenesis by promoting BMAL1 degradation and suppressing the MAPK\\u2013C/EBP\\u03b2 and KLF15 programs [#11, #12]. In cancer, BMAL2 acts as a direct promoter-binding transcriptional regulator of metabolic and survival genes \\u2014 it transactivates ACOT7, MRPL15, SLC7A11, SLC31A1/ENO1, and ANXA2 to support glycolysis and suppress ferroptosis, represses AMOTL2 to enhance YAP nuclear activity, stabilizes HIF1A while destabilizing HIF2A downstream of KRAS, and sustains RAD51-dependent homologous recombination repair [#13, #22, #20, #16, #23, #15, #24, #21]. In immune cells it binds the Il21 and PD-L1 promoters to control IL-21 production, thymocyte apoptosis, and macrophage endotoxin tolerance [#8, #10, #17]. BMAL2 protein is targeted for ubiquitin-proteasome degradation by melatonin and by a high-affinity small-molecule ligand, providing pharmacological handles on its activity [#20, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established BMAL2 as a bHLH-PAS factor that partners with circadian and hypoxia transcription factors, defining its molecular identity and candidate partners.\",\n      \"evidence\": \"Heterodimer formation and transcriptional activity assays with CLOCK, NPAS2, HIF1\\u03b1; SCN co-expression; cDNA cloning and tissue expression analysis\",\n      \"pmids\": [\"10864977\", \"10964693\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous target genes not yet defined\", \"Functional consequence of HIF1\\u03b1 partnership not tested in vivo\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed that CLOCK:BMAL2 transcriptional amplitude is tunable by alternative splicing and by BMAL2 dosage, indicating bidirectional regulatory behavior rather than a simple activator role.\",\n      \"evidence\": \"RT-PCR splice variant identification and luciferase reporter assays on Per1, vasopressin, PAI-1 promoters; chicken ortholog overexpression in pineal cells\",\n      \"pmids\": [\"12055078\", \"11554928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological splice-isoform abundance unknown\", \"Mechanism of dose-dependent repression not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated that CLOCK:BMAL2 contributes additively with CLOCK:BMAL1 to E-box-driven promoter activity and is suppressed redox-independently by PER/CRY, positioning it within the clock feedback loop.\",\n      \"evidence\": \"Luciferase reporter assays with E-box mutants in endothelial cells (PAI-1 promoter); antisense BMAL2 cell-cycle and colony assays\",\n      \"pmids\": [\"12738229\", \"12917632\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous occupancy of PAI-1 E-boxes not shown\", \"Proliferation phenotype mechanism uncharacterized\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved paralog-specific repression: PER2 preferentially binds and inhibits BMAL2, while CRY2 preferentially inhibits BMAL1, and BMAL2 knockdown blunts cellular clock rhythms.\",\n      \"evidence\": \"Co-immunoprecipitation, luciferase reporter assays, siRNA with Bmal1-promoter bioluminescence rhythm monitoring\",\n      \"pmids\": [\"19605937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of differential PER2/CRY2 binding unknown\", \"Cell-type generality of rhythm contribution untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Proved BMAL1/BMAL2 functional redundancy by genetic rescue, reframing BMAL2 as a bona fide core clock and metabolic regulator rather than an accessory factor.\",\n      \"evidence\": \"Transgenic constitutive BMAL2 rescue of Bmal1-knockout mice with locomotor and metabolic phenotyping\",\n      \"pmids\": [\"20153195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous tissue-specific roles of BMAL2 not separated from BMAL1\", \"Whether redundancy is reciprocal in all tissues unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a direct immunoregulatory target, showing ARNTL2 binds the Il21 promoter allele-specifically and represses IL-21 to control T-cell numbers.\",\n      \"evidence\": \"ChIP at Il21 promoter, transcriptome analysis, T-cell quantification in congenic mice\",\n      \"pmids\": [\"24520124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether repression requires CLOCK heterodimer not addressed\", \"Direct vs indirect effect on T-cell subsets unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established BMAL2 as a driver of cancer metastasis and immune phenotypes, linking its transcriptional output to a pro-metastatic secretome and to thymocyte apoptosis via IL-21 epistasis.\",\n      \"evidence\": \"In vivo lung adenocarcinoma metastasis assays, CLOCK Co-IP, SMOC2 validation; Arntl2-knockout thymocyte assays with IL-21 rescue\",\n      \"pmids\": [\"27150038\", \"27671790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter targets of the secretome program not mapped\", \"Upstream signals activating BMAL2 in tumors not defined here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected inflammatory signaling to BMAL2 regulation, showing TNF drives NF-\\u03baB-dependent ARNTL2/NPAS2 induction and nuclear localization, while the ARNTL2/NPAS2 dimer is a weaker clock-gene inducer than ARNTL1/NPAS2.\",\n      \"evidence\": \"Reporter assays in HEK293, immunofluorescence, RT-qPCR with IKK-2 inhibitor in human fibroblasts\",\n      \"pmids\": [\"30210560\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of TNF\\u2013ARNTL2 axis untested\", \"Functional outcome of weaker clock-gene induction unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a feedback role in adipogenesis whereby ARNTL2 destabilizes BMAL1 and suppresses MAPK\\u2013C/EBP\\u03b2/KLF15, with its own stability set by mTOR/MAPK signaling.\",\n      \"evidence\": \"Overexpression, siRNA, Western blot, gene expression in human adipose stem/progenitor cells\",\n      \"pmids\": [\"36329012\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of BMAL1 degradation not detailed\", \"Direct transcriptional targets vs signaling effects not separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Began mapping direct cancer target promoters, showing ARNTL2 transactivates ACOT7 to drive fatty acid synthesis and suppress ferroptosis in NSCLC.\",\n      \"evidence\": \"Dual luciferase, ChIP-qPCR, gain/loss-of-function, ferroptosis/apoptosis assays\",\n      \"pmids\": [\"37003979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Requirement for CLOCK heterodimer at ACOT7 not tested\", \"Whether circadian timing modulates ACOT7 regulation unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Through a dedicated knockout, established BMAL2 as a non-redundant regulator of period length, SCN metabolic gene rhythms, food-anticipatory activity, and systemic energy balance.\",\n      \"evidence\": \"Bmal2-knockout mice with locomotor, feeding, and metabolic phenotyping and SCN/hypothalamic gene expression\",\n      \"pmids\": [\"38531632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SCN target genes underlying period change not identified\", \"Cell-autonomous vs circuit-level contributions unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the direct-target repertoire across cancers, showing BMAL2 represses AMOTL2 to activate YAP, upregulates SLC31A1/ENO1 glycolysis, enhances HIF1A-driven aerobic glycolysis, and is itself epigenetically activated at its promoter and induced via TREM-1 to drive PD-L1.\",\n      \"evidence\": \"ChIP, luciferase, glycolysis/invasion assays, xenografts (NPC, bladder, AML/NSCLC); LINC01232/p300 RIP-ChIP; CRISPR activation with BIAcore PD-L1 binding\",\n      \"pmids\": [\"38956029\", \"39147318\", \"38660843\", \"39268727\", \"38938563\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HIF1A link (idx 18) is Low-confidence and single-study\", \"Direct vs cofactor-dependent binding at several promoters not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Consolidated BMAL2 as a multi-target transcriptional driver of cancer metabolism, ferroptosis resistance, and DNA repair, and identified druggable degradation as a therapeutic strategy.\",\n      \"evidence\": \"ChIP/luciferase for SLC7A11, MRPL15, ANXA2; HIF1A/HIF2A stability in PDAC (preprint); RAD51/HR and DNA-damage assays with small-molecule degrader; melatonin-induced ubiquitin-proteasome degradation; Bmal2-KO obesity phenotyping\",\n      \"pmids\": [\"40753759\", \"41075325\", \"41243277\", \"36993718\", \"41933240\", \"40983272\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether a single DNA-binding mode unifies these diverse targets is unknown\", \"Mechanism distinguishing HIF1A stabilization from HIF2A destabilization not defined\", \"Degrader specificity over BMAL1 not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how BMAL2 selects between activator and repressor modes and between its circadian, metabolic, immune, and oncogenic target genes, and whether these cancer targets require CLOCK/NPAS2 heterodimerization and circadian timing.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genome-wide endogenous BMAL2 occupancy map across contexts\", \"Structural determinants of paralog-specific cofactor binding undefined\", \"Causal Mendelian disease link not established in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 4, 6, 8, 13, 15, 16, 20, 22, 23]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 8, 13, 15, 20, 22, 23]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [0, 6, 7, 14]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 8, 13, 22, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [12, 14, 16, 18, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 13, 15, 16, 20, 21, 22, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 10, 17]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CLOCK\", \"NPAS2\", \"HIF1A\", \"PER2\", \"CRY2\", \"BMAL1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}